PD42 - PD42: Bladder Cancer: Basic Research & Pathophysiology III

Podium Presenter(s)

• 

  Russell Becker, MD

  Johns Hopkins Medicine

  PDF Slides and Audio
• 

  Timothy Clinton, MD

  Memorial Sloan Kettering Cancer Center

  PDF Slides and Audio
• JF

  James Ferguson
• MK

  Masatomo Kaneko

  USC Institute of Urology and Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

  PDF Slides and Audio
• KK

  Kohei Kobatake, MD

  PDF Slides and Audio
• AK

  Andrea Kokorovic, MD,MSc

  The University of Texas MD Anderson Cancer Center

  PDF Slides and Audio
• YL

  Yan LIU
• 

  Joshua Meeks, MD,PhD

  Northwestern University
• AP

  Ana Cristina Plata Bello, MD

  University Hospital of Canary Islands, Spain

  PDF Slides
• 

  Come Tholomier, MD

  McGill University Health Centre

  PDF Slides and Audio
• 

  Chiahao Wu, MS

  Full time graduate student
  University of Rochester

  PDF Slides and Audio

Presentations:

• 7:00 AM – 9:00 AM

  PD42-01: Residual muscle-invasive disease at cystectomy is not accurately predicted by post-chemotherapy restaging protocols including DNA damage response gene mutation analysis
  Russell Becker, MD
• 7:00 AM – 9:00 AM

  PD42-02: Optimizing sequence of therapy and radiation delivery when combined with PD-L1 immune-checkpoint inhibition in bladder cancer
  Come Tholomier, MD
• 7:00 AM – 9:00 AM

  PD42-03: Association of Pathologic Response to Neoadjuvant Pembrolizumab with Tumor Subtype from the PURE01 Study
  Joshua J. Meeks, MD,PhD
• 7:00 AM – 9:00 AM

  PD42-04: The dysbiosis of microbiota affects bladder inflammation and carcinogenesis of muscle invasive bladder cancer.
  Yan LIU
• 7:00 AM – 9:00 AM

  PD42-05: Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization and causes bladder cancer in cooperation with p53 dysfunction
  Kohei Kobatake, MD – Institute of Biomedical and Health Sciences, Hiros
• 7:00 AM – 9:00 AM

  PD42-06: DEFINING THE GENETIC EVOLUTION OF EPIGENETIC ALTERATIONS IN BLADDER CANCER
  Timothy N. Clinton, MD
• 7:00 AM – 9:00 AM

  PD42-07: Investigating the synthetic lethality of Enhancer of zeste homolog 2 (EZH2) inhibition in AT-rich interactive domain-containing protein 1A (ARID1A) mutant bladder cancer
  James Ferguson
• 7:00 AM – 9:00 AM

  PD42-08: Novel combination therapy using lentiviral interferon and immune checkpoint blockade for treatment of bladder cancer in a murine model
  Andrea Kokorovic, MD,MSc – The University of Texas MD Anderson Cancer Center
• 7:00 AM – 9:00 AM

  PD42-09: Urine cell image analysis using a deep learning model
  Masatomo Kaneko
• 7:00 AM – 9:00 AM

  PD42-10: Role of Extracellular Vesicle-Borne Protein Disulfide Isomerase in Bladder Tumorigenesis.
  Chiahao Wu, MS – University of Rochester
• 7:00 AM – 9:00 AM

  PD42-11: Cigarette Smoke, E-cigarettes and Bladder Cancer Cell-Derived Extracellular Vesicles induce Bladder Carcinogenesis.
  Chiahao Wu, MS – University of Rochester
• 7:00 AM – 9:00 AM

  PD42-12: Prospective randomized clinical trial of chemohyperthermia with mitomycin-C prior to transurethral resection of the bladder and its relationship with the rate of early recurrence in non-muscle invasive bladder cancer: intermediate analysis.
  Ana Cristina Plata Bello, MD – Hospital Universitario De Canarias